Prometic Life Sciences Inc.
ProMetic is a biopharmaceutical corporation with globally recognized expertise in bioseparation and uses its own affinity technology for the development of best in class plasma-derived therapeutics. ProMetic is also active in developing its own novel small molecule therapeutics products.
Headquartered in Laval, Canada, ProMetic has a global presence through its various sites in the UK and USA, providing both manufacturing and R&D capability. These strategic locations facilitate ProMetic’s growth globally and supports all business activity in American, European and Asian markets.
ProMetic is publicly traded on TSX (Symbol: PLI) and OTCQX (Symbol: PFSCF).
ProMetic has developed core competencies in strategic fields, including:
- Purification of biologics
- Drug development
- Elimination of pathogens
The business is now focused on developing its range of therapeutics from both its plasma-derived and small-molecule platform.
Prometic Biosciences Inc. develops unique innovative therapeutics, orally active compounds that target multiple uncovered medical needs in the fields of hematology, oncology, nephrology, fibrosis and autoimmune diseases. The department of